Article Figures & Data
Tables
- Table 1.
Demographic and disease-related characteristics. All data are mean (SD) or n (%).
Characteristics Women, n = 71 Men, n = 16 Overall, n = 87 Age, yrs 28.7 (10.1) 31.4 (13.8) 29.2 (10.8) Height, m 1.6 (0.1) 1.7 (0.1) 1.6 (0.9) Weight, kg 60.2 (16.0) 67.6 (18.6) 61.5 (16.7) Body mass index, kg/m2 23.4 (5.3) 24.1 (6.2) 23.5 (5.5) Disease duration, yrs 20.6 (11.0) 24.0 (13.6) 21.2 (11.5) Current smoker 16 (22.5) 2 (22.2) 18 (22.5) Disease characteristics and treatment Disease subtype (ILAR) Systemic 7 (9.9) 5 (1.3) 12 (13.8) Oligoarticular 12 (16.9) 3 (18.8) 15 (17.2) Extended oligoarticular 8 (11.3) 0 8 (9.2) Polyarticular RF-positive 17 (23.9) 1 (6.3) 18 (20.7) Polyarticular RF-negative 21 (29.6) 2 (12.5) 23 (26.4) Psoriasis 3 (4.2) 2 (12.5) 5 (5.8) Enthesitis-related 2 (2.8) 2 (12.5) 4 (4.6) Other 1 (1.41) 1 (6.3) 2 (2.3) RF-positive 21 (29.6) 1 (6.3) 22 (25.3) HAQ score (0–3) 1.3 (0.8) 1.5 (0.8) 1.3 (0.8) ESR, mm/h 23.2 (20.0) 21.0 (26.3) 23.0 (20.5) CRP, mg/l 17.8 (20.9) 26.3 (29.2) 19.2 (22.3) Large-joint arthroplasty (yes vs no) 16 (22.5) 4 (66.7) 20 (26.0) Hip arthroplasty (yes vs no) 15 (21.1) 4 (66.7) 19 (24.7) Knee arthroplasty (yes vs no) 12 (16.9) 4 (66.7) 16 (20.8) Methotrexate (ever, yes vs no) 20 (29.0) 2 (25.0) 22 (28.6) Other DMARD (ever, yes vs no) 33 (46.5) 6 (37.5) 39 (44.8) Oral steroids (ever, yes vs no) 34 (49.3) 5 (62.5) 39 (50.7) Duration of oral steroids, mo 76.3 (90.1) 19.0 (24.0) 72.9 (88.5) -
ILAR: International League of Associations for Rheumatology; RF: rheumatoid factor; HAQ: Health Assessment Questionnaire; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; DMARD: disease-modifying antirheumatic drug.
-
- Table 2.
Areal bone mineral density (BMDa) and Z-score at the lumbar spine and total hip. Data are mean (95% CI).
Women Men BMDa Lumbar spine, g/cm2 0.982 (0.947, 1.018) 1.028 (0.910, 1.146) Total hip, g/cm2 0.817 (0.761, 0.874) 0.857 (0.665, 1.050) Z-score Lumbar spine −0.328 (−0.657, 0.001) −0.251 (−1.266, 0.764) Total hip −0.542 (−0.975, −0.109) −0.176 (−2.323, 1.971) - Table 3.
Influence of disease-related factors on areal bone mineral density (BMDa) at the lumbar spine and total hip. Results are expressed as ß-coefficient (95% CI) adjusted for age and sex.
Lumbar Spine BMDa (g/cm2) Total Hip BMDa (g/cm2) Weight, kg 0.005 (0.003, 0.007)* 0.006 (0.003, 0.009)* Height, cm 0.007 (0.004, 0.011)* 0.012 (0.005, 0.019)* Age at scan, yrs 0.004 (0.001, 0.007)* 0.000 (−0.006, 0.006) Sex (F vs M) −0.046 (−0.136, 0.045) −0.040 (−0.195, 0.114) Disease duration, yrs −0.005 (−0.011, 0.001) −0.004 (−0.015, 0.006) HAQ score (0–3) −0.099 (−0.148, − 0.051)* −0.122 (−0.217, −0.026)* ESR, mm/h 0.000 (−0.002, 0.003) 0.002 (−0.004, 0.007) ESR, mm/h < 20 Referent Referent ≥ 20 −0.007 (−0.110, 0.097) 0.057 (−0.142, 0.255) CRP, mg/l −0.001 (−0.004, 0.001) −0.001 (−0.005, 0.003) RF-positive (yes vs no) 0.023 (−0.058, 0.103) 0.057 (−0.065, 0.178) Disease subtype Oligoarticular Referent Referent Systemic −0.108 (−0.222, 0.007) −0.180 (−0.382, 0.022) Extended oligoarticular −0.034 (−0.167, 0.098) −0.280 (−0.496, −0.064)* Polyarticular RF-positive −0.101 (−0.205, 0.003) −0.098 (−0.266, 0.070) Polyarticular RF-negative −0.090 (−0.190, 0.009) −0.184 (−0.343, − 0.025)* Psoriasis 0.036 (−0.116, 0.188) 0.074 (−0.154, 0.302) Enthesitis-related 0.212 (0.044, 0.379)* 0.053 (−0.226, 0.333) Other −0.062 (−0.287, 0.163) 0.072 (−0.267, 0.411) Oral corticosteroids (yes vs no) −0.143 (−0.211, −0.075)* −0.136 (−0.248, −0.024)* Methotrexate (yes vs no) −0.071 (−0.154, 0.013) 0.015 (−0.112, 0.143) Large-joint replacement (yes vs no) −0.101 (−0.188, −0.013)* −0.194 (−0.343, −0.046)* -
↵* p < 0.05. RF: rheumatoid factor; HAQ: Health Assessment Questionnaire; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein.
-